DEADLINE APPROACHING: Berger Montague Advises ADMA Biologics, Inc. (NASDAQ: ADMA) Investors to Inquire About a Securities Fraud Class Action by August 10, 2026

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA ) ("ADMA" or the "Company") on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired ADMA securities during the Class Period may, no later than August 10, 2026 , seek to be appointed as a lead plaintiff representative of the class.

Headquartered in Ramsey, NJ, ADMA is a biopharmaceutical company focused on specialty biologics, including treatments for immune deficiencies and infectious diseases. Its flagship product, ASCENIV, is a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency.

On March 24, 2026, financial analyst Culper Research published a report titled, "ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported." The report alleged that in 2025, ADMA was able to "report revenue growth that was never there" by inducing one of its distributors to "stock excess ASCENIV by offering rebates and extended payment terms…." According to Culper Research, had ADMA not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.

On this news, ADMA shares declined $2.26 per share, or 16%, from a closing price of $13.59 per share on March 23, 2026, to a close of $11.33 per share on March 24, 2026. Shares fell an additional $1.70 per share (15%) the following day, closing at $9.63 per share on March 25, 2026.